NCT07203404View on ClinicalTrials.gov

A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

July 24, 2025

Primary Completion Date

July 23, 2027

Study Completion Date

July 23, 2028

Conditions
SLELNANCA Associated VasculitisANCA-Associated GlomerulonephritisAnti-GBM DiseaseMNSScIIM
Interventions
DRUG

RD06-05 CART Cell Injection

CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide

Trial Locations (1)

Unknown

RECRUITING

Bioheng Study site, Shanghai

All Listed Sponsors
lead

Nanjing Bioheng Biotech Co., Ltd.

INDUSTRY